DRAFT

Advisory Committee Meeting Communication Survey

FDA is looking to identify ways to enhance the communication that occurs between FDA and the public at Advisory Committee meetings. We would appreciate your feedback based on the meeting you attended today.

Your participation/non-participation is completely voluntary and your responses will not have an affect on your eligibility for receipt of any FDA services. All respondent identification and information are confidential and will be anonymous unless otherwise indicated. In instances where respondent identity is needed (e.g., for follow-up of non-respondents), this information collection fully complies with all aspects of the Privacy Act.

1. What	is your affiliat	ion? (Circle c	one)					
Industry	Trade Association	Advocacy Group	FDA Staff	Press	Clinical Practitioner	Patient	General Public	Other (please specify)
2. What •								

3. Please indicate your level of agreement with each of the following statements. Feel free to elaborate on your response in the space provided.

1 - Strongly Disagree, 2 - Disagree, 3 - Neither Agree Nor Disagree, 4 - Agree, 5 - Strongly Agree

Communication Topic			_	eme			Comments
The meeting provided an opportunity for the public to communicate their perspectives to the FDA Advisory Committee members.	1	2	3	4	5	N/A	
The meeting provided an opportunity for the FDA to communicate information to the public.	1	2	3	4	5	N/A	
The meeting was announced with enough time for me to plan my attendance.	1	2	3	4	5	N/A	
The meeting location was convenient.	1	2	3	4	5	N/A	
The meeting time was convenient.	1	2	3	4	5	N/A	
Providing materials <u>online before</u> the meeting was useful.	1	2	3	4	5	N/A	
Providing materials <u>during the meeting</u> was useful.	1	2	3	4	5	N/A	
The content of the materials provided was useful.	1	2	3	4	5	N/A	
I could clearly hear all speakers during the meeting.	1	2	3	4	5	N/A	

Additional questions are located on the back of this page.

4. How did you find out about today's meeting? (Circle all that apply)

DRAFT

FDA Website	FDA listserv ema	il Federal Reg	ister	Trade Publication		
Social Media	Advocacy group			e: Other (please specify)		
5. Which additional charmeetings? (Circle all that		on would you like to se	e used to announ	ice future Advisory Committee		
FDA Website (e o Twitter	nail Text message serv) alerts (SMS)	Other (ple	Other (please specify)		
6. Which of the followin Committee meetings? (C		nication would you like	e to see used to b i	roadcast future Advisory		
. =	esentations Third-par ia webcam broad	streaming	Other (please s	specify)		
7. Which of the followin day of the meeting? (Circ	-	useful to you if they w	ere available on th	ne FDA website following the final		
Meeting Webca Summary video (24 hours) (24 hou	presentation slide	ranscripts (3 – 4 weeks)	Meeting minutes - 3 months)	Other (please specify)		
8. Was anything about t explain.	he meeting especially	helpful in facilitating c	ommunication be	tween FDA and the public? Please		
9. Do you have any sugg meetings?	estions for improving	communication before	e, during or after f	uture Advisory Committee		

Thank you for your time - we appreciate your feedback!